EGFR and ovarian carcinoma: Moreover, as only 30% of ovarian cancers express Her-2/neu or EGFR (Rosen et al, 2006), it can be suggested that the varying degrees of P-STAT3 expression exhibited by all the ovarian tumours analysed in our study may result due to the activation or upregulation of alternative cytokine or growth factor receptor pathways.